These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8914007)

  • 1. Detectable levels of IgM antibodies to hepatitis C virus core protein predict breakthrough in patients with chronic hepatitis C treated with interferon-alpha.
    Fracassetti O; Tambini R; Perani V; Vicari O; Lorenzi N; Delvecchio G
    J Viral Hepat; 1996 Sep; 3(5):265-6. PubMed ID: 8914007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C.
    Pawlotsky JM; Roudot-Thoraval F; Bastie A; Darthuy F; Rémiré J; Métreau JM; Zafrani ES; Duval J; Dhumeaux D
    J Infect Dis; 1996 Jul; 174(1):1-7. PubMed ID: 8655978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-treatment levels of anti-HCV core IgM antibodies are closely associated with response to alpha interferon therapy in chronic hepatitis C patients.
    Tabone M; Secreto P; Marini C; Bonardi R; Boero M; Taraglio S; Ercole E; Sallio Bruno F; Pera A
    Eur J Gastroenterol Hepatol; 1997 Mar; 9(3):287-91. PubMed ID: 9096432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
    Pawlotsky JM; Darthuy F; Rémiré J; Pellet C; Udin L; Stuyver L; Roudot-Thoraval F; Duvoux C; Douvin C; Mallat A
    J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of serum immunoglobulin M to hepatitis C virus core in patients with chronic hepatitis C.
    Tran A; Yang G; Dreyfus G; Rouquié P; Durant J; Rampal A; Rampal P; Benzaken S
    Am J Gastroenterol; 1997 Oct; 92(10):1835-8. PubMed ID: 9382047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of IgM antibodies to hepatitis C virus in patients with chronic hepatitis C undergoing interferon-alpha therapy. Analysis by two different methods.
    Torronteras R; Sánchez-Quijano A; Abad MA; Soto B; Andreu J; Medrano FJ; Leal M; Lissen E
    J Viral Hepat; 1994; 1(2):159-61. PubMed ID: 8790572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are basal core-IgM antibodies to hepatitis C virus predictive of successful alpha-interferon therapy?
    Pawlotsky JM; Roudot-Thoraval F; Bastie A; Duval J; Dhumeaux D
    J Hepatol; 1995 Dec; 23(6):760-1. PubMed ID: 8750179
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome.
    Quiroga JA; van Binsbergen J; Wang CY; Pardo M; Navas S; Trines C; Herrero M; Carreño V
    Hepatology; 1995 Dec; 22(6):1635-40. PubMed ID: 7489967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
    Hayashi PH; Beames MP; Kuhns MC; Hoofnagle JH; Di Bisceglie AM
    Am J Gastroenterol; 1996 Nov; 91(11):2323-8. PubMed ID: 8931411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acute hepatitis C with interferon alfa-2b.
    Tocci G; Visco-Comandini U; Antonucci G
    N Engl J Med; 2002 Apr; 346(14):1091-2. PubMed ID: 11936121
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum levels of anti-hepatitis C virus IgM core antibodies may predict the response to interferon-alpha therapy in chronic hepatitis C.
    Tabone M; Galatola G; Secreto P; Marini C; Molinaro G; Aricò' S
    J Viral Hepat; 1994; 1(2):155-7. PubMed ID: 8790571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha.
    Löhr HF; Elste C; Dienes HP; Michel G; Braun HB; Meyer zum Büschenfelde KH; Gerken G
    J Hepatol; 1996 Sep; 25(3):292-300. PubMed ID: 8895007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of IgG and IgM HCV antibody secretion in vitro in patients with chronic hepatitis C: correlation with disease activity and response to interferon-alpha.
    Löhr H; Nagel C; Dienes HP; Simpson B; Michel G; Goergen B; Meyer zum Büschenfelde KH; Gerken G
    Hepatology; 1994 Dec; 20(6):1383-9. PubMed ID: 7526999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C.
    Baumert TF; Wellnitz S; Aono S; Satoi J; Herion D; Tilman Gerlach J; Pape GR; Lau JY; Hoofnagle JH; Blum HE; Liang TJ
    Hepatology; 2000 Sep; 32(3):610-7. PubMed ID: 10960457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antibodies generated against hepatitis C virus (HCV) core antigen: IgM and IgA antibody against HCV core].
    Sato S; Fujiyama S; Chikazawa H; Tanaka M
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):253-9. PubMed ID: 7563714
    [No Abstract]   [Full Text] [Related]  

  • 16. The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon.
    Negro F; Abate ML; Mondardini A; Baldi M; Leandro G; Lombardi S; Wolfe L; Ryff JC; Verme G; Brunetto MR
    J Viral Hepat; 1995; 2(4):171-4. PubMed ID: 7489343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus.
    Tassopoulos NC; Hatzakis AE; Papatheodoridis GV; Karvountzis G; Troonen H; Lennartz L
    J Hepatol; 1994 Feb; 20(2):305-6. PubMed ID: 7516362
    [No Abstract]   [Full Text] [Related]  

  • 20. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.